Introduction

P
rostate cancer (PCa) is the most common non-skin cancer among men, with its incidence being variable in most countries (Hsing et al., 2000) . However, in India its incidence is low, and it ranks as the sixth most commonly diagnosed cancer in men (Sinha et al., 2003) . Despite its high incidence and morbidity, the etiology of PCa is still unknown. There is still limited data published on the mechanisms of carcinogenesis of PCa (Ribeiro et al., 2004; Bott et al., 2005) . However, it has been suggested that genetic polymorphisms may influence an individual's susceptibility to PCa.
DNA repair is an important mechanism for maintaining the integrity of DNA. The key DNA repair pathways that are often associated with cancer risk include base excision repair, nucleotide excision repair, and homologous recombination repair. Single nucleotide polymorphisms located in DNArepair genes could be responsible for serious alterations in DNA repair capacity (DRC) (Andreassen et al., 2002) . Several studies have demonstrated that polymorphisms in DNA repair genes that are responsible for maintaining genomic integrity are modifiers of disease risk (Berwick and Vineis, 2000; Vodicka et al., 2004) .
The XRCC3 (located in the 14q32.3 region) gene product is involved in the homologous recombination and repair pathway. XRCC3 participates in DNA double-strand break (DSB)/recombination repair and is a member of the Rad-51-related protein family. Rad-51-like proteins are known to participate in homologous recombination to maintain chromosome stability and repair DNA damage (Manuguerra et al., 2006) . Carriers of the XRCC3 variant allele (exon7, C18067T) exhibit relatively high DNA adduct (covalent adducts between cancer causing chemicals and DNA) levels in lymphocyte DNA, indicating that this polymorphism may be associated with a relatively low DRC (Synowiec et al., 2008) . Molecular epidemiological studies have shown that this XRCC3 polymorphism is associated with increased risk of breast, gastric carcinoma (Kuschel et al., 2002; Shen et al., 2004) . Therefore, XRCC3 has been of considerable interest as a candidate susceptibility gene for cancer. Similarly, the XRCC7 gene product primarily participates in the repair of DSBs via the nonhomologous end-joining (NHEJ) mechanism (Khanna and Jackson, 2001) .
The XRCC7 gene (located on chromosome 8q12), also known as PRKDC (protein kinase, DNA-activated, catalytic polypeptide), encodes DNA-PKcs (protein kinases). As the catalytic subunit of the DNAPK complex, XRCC7 aids in the recognition and repair of DSBs. The variant allele G6721T in XRCC7 intron 8 may also represent an increased risk of cancer .
In the present study, we investigated functional variants of XRCC3 and XRCC7 and their implication in the pathogenesis of PCa to augment the effects of individual polymorphisms and enhance cancer risk assessment in North Indian cohort.
Materials and Methods
Study subjects
The present study was hospital-based and both cases and controls were enrolled in the Department of Urology (Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow) between January 2007 and December 2009. The participants in this study were unrelated individuals of similar ethnicity from Lucknow and other adjoining cities of North India. All symptomatic men for lower urinary tract infection (LUTS) suspected to have PCa based on serum prostatespecific antigen (PSA) >4 ng/mL and/or abnormal digital rectal examination had transrectal systematic ultrasoundguided needle biopsies. The primary end point was the histologic presence of adenocarcinoma of the prostate in the biopsy specimen. Tumor grade was evaluated in PCa samples by the Gleason scoring system (Gleason and Mellinger, 1974) . The two most common patterns of growth (well differentiated and poorly differentiated) were combined to a score. A total of 192 histologically confirmed patients with PCa were enrolled for the study. Bone scan was conducted in patients suspected with bone metastasis.
We randomly selected 224 cancer free, unrelated, age matched healthy control individuals from similar ethnicity. PSA assay was done in all the control individuals, and those with total PSA !4 ng/mL or with a history of cancer were excluded from the study. Serum PSA was assayed by sandwich ELISA using Can gen PSA kit. Informed consent was obtained from each subject while interviewing for demographic details and blood sample collection. The institutional ethical committee approved this study.
DNA extraction and genotype analysis
Standard venipuncture was used to collect 5 mL of peripheral blood samples from all study participants in tubes containing ethylenediaminetetraacetic acid as an anticoagulant and stored at À708C. The genomic DNA was extracted from the stored peripheral blood samples using salting out method (Miller et al., 1988) .
The polymorphic sites in XRCC3 (Exon 7 C18067T, rs861539 and IVS5-14 A17893G, rs1799796) and XRCC7 (Intron 8 G6721T, rs7003908) genes were amplified by polymerase chain reaction (PCR) combined with restriction fragment-length polymorphism using primers implying conditions, as previously described (Ló pez-Cima et al., 2007; Wang et al., 2008; Werbrouck et al., 2008) . PCR cocktail comprised of 10 pmol of each primer; 100 ng genomic DNA; 0.25 mM each of deoxyribonucleotide triphosphate; and 1Â PCR buffer containing 10 mM Tris-HCl, pH 8.6, 50 mM KCl, 1.5 mM MgCl 2 , and 0.5 units of Taq polymerase (Bangalore Genei). Amplified products were digested using restriction enzyme NcoI for XRCC3 Exon 7 (C > T) and PvuII (MBI Fermentas Inc.) for XRCC3 IVS5-14 (A > G) and XRCC7 Intron 8 (G > T), respectively. Subsequently, fragments of XRCC3 and XRCC7 were resolved on 10% PAGE and 2% agarose gels, to identify wild type and polymorphic variant.
Quality control procedures
Precise quality control procedures were applied during the genotyping process. As a negative control, a PCR mix without a DNA sample was used to ensure the accuracy of the method used. Samples that failed to genotype were scored as missing and subjected to repetition. Five percent of samples from patients and controls, including samples of each genotype, were sequenced to evaluate the quality of genotyping, which showed 100% concordance. Genotyping was performed without knowledge of the case or control status.
Statistical analyses
Power of the study was calculated using Quanto software version 1.0 (http://hydra.usc.edu/gxe) with input of the following variables; Case-Control Study Design, Significance Level (a) <0.05 (two-sided), Model of inheritance ¼ log additive, allele freq, and genetic effect for odds ratio (OR) (!1.6 or 0.6). The present study achieved 80% of the statistical power. A two-tailed p-value of <0.05 was considered statistically significant. Chi-square (w 2 ) analysis was used to assess deviation from Hardy-Weinberg's equilibrium and to compare the genotype/allele/diplotype frequency between patients and controls. ORs was obtained by unconditional logistic regression analysis and adjusted for age as a continuous variable. Patients with PCa and different Gleason grades or bone metastasis were identified using the same statistics as mentioned. Statistical significance was set at p < 0.05. All the statistical analysis was conducted using the SPSS software, version 11.5 (SPSS, Inc.).
Results
Demographical and clinical details of study subjects
A total of 416 individuals (192 PCa and 224 controls) were analyzed in the study. There was no statistical difference between age of the patients (59.1 AE 10.4 years) and healthy controls (62.6 AE 8.9 years) or their smoking habits ( p ¼ 0.327). As expected, there was high degree of statistical difference between serum PSA of patients with PCa (221 AE 57.4 ng/mL) and controls with PCa (2.3 AE 0.8 ng/mL). The majority of the patients had high Gleason grades at the time of diagnosis (Gleason score 7 in 29.7% of PCa, and Gleason score >7 in 44.8% of PCa), and 41.8% of patients were diagnosed to have bone metastasis (Table 1) .
Association of XRCC3 and XRCC7 genotype variants with PCa risk
The genotypic distributions of all three gene polymorphism in the controls were in Hardy-Weinberg's equilibrium. To evaluate the association between genetic variant with risk of PCa, we compared XRCC3 Exon 7, XRCC3 IVS5-14, and XRCC7 Intron 8 genotype frequency distribution in the PCa and control group is shown in Association between the XRCC3 Exon 7, IVS5-14, and XRCC7 Intron 8 gene variants and their risks associated with bone metastasis were also investigated. The patients with PCa were stratified into two groups, one with positive and the other with negative bone metastasis. These two groups, 
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however, demonstrated no association with any of these three gene polymorphisms with the risk of PCa (Table 5 ).
Interaction of XRCC3 and XRCC7 polymorphism with smoking habit in PCa patients
We evaluated the gene-smoking interaction to study the modulation of PCa risk with regard to XRCC3 Exon 7, IVS5-14, and XRCC7 Intron 8 gene polymorphisms. We grouped the patients with PCa into two groups: nonsmokers (never smoked) and smokers (smoking for >5 years). On analyzing the genotype frequency between these two groups for susceptibility to PCa, none of these polymorphisms demonstrated association (data not shown).
Discussion
Cancer is a complex disease that is influenced by the interplay between multiple genetic and environmental factors, and, thus, it is unlikely that individual genes and/or single nucleotide polymorphisms would have substantial effects on the overall risk. Interest in recent years has focused on the population-wide variability in repair capacity phenotypes, which appears to account for a several-fold variation in cancer risk.
In this hospital-based case-control study, we examined the influence of DRC of homologous recombination (XRCC3-Exon7, XRCC3 IVS5-14) and NHEJ (XRCC7 Intron8) genes for PCa susceptibility. Our data revealed increased risk of PCa in individuals with GG genotype of the XRCC7 Intron 8. The combined genotype of XRCC3 Exon 7 and IVS5-14 was found to be associated with PCa risk.
Disruption of genomic integrity contributes to malignant transformation and subsequent cancer development. The repair of DNA damage plays a key role in maintaining genomic integrity. The role of the major DNA repair pathways is mainly responsible for the removal of bulky DNA adducts induced by chemical carcinogens (Aboussekhra et al., 1995; Wood, 1999) . These pathways thus involve sequential reaction steps, including DNA damage recognition, incision of damaged DNA, repair of the gapped DNA, and DNA ligation (Sancar et al., 2004) . The XRCC3 variant, T241M, has been reported to be associated with an increased risk of some cancers (Lindh et al., 2006) . However, a recent experimental study did not show a functional difference between the 241 variant and the common genotype of XRCC3 in homologous recombination repair of DNA in XRCC3-deficient irs1SF cells (or in sensitivity to the inter-strand cross-linking agent mitomycin C) (Shen et al., 2003) .
In our study, no significant association was observed with the susceptibility to PCa in XRCC3. Smoking too had no influence (data not shown). The genotype frequency in healthy controls in our study was consistent with the other reported Indian studies on XRCC3 and XRCC7 (Gangwar et al., 2009) . However, the present study did not illustrate any significant risk between XRCC3 Exon 7 (C > T) and IVS5-14 (A > G) and PCa risk. Previous reports have suggested XRCC3 Exon 7 (C > T) polymorphism to be associated with melanoma development in Caucasians and with breast cancer in white Anglo-Saxons (Winsey et al., 2000; Kuschel et al., 2002) but not among South Australians and Japanese men with PCa (Tatsuya et al., 2008; Dhillon et al., 2009) .
To the best of our knowledge, there has been no report on association with the risk of PCa with XRCC3, IVS5-14 (A > G) gene polymorphism, which is found in noncoding regions. No significant association with XRCC3 IVS5-14 gene The XRCC7 gene is involved in the NHEJ pathway, which is responsible for repairing most DSBs (Hopfner et al., 2002) . The expression of XRCC7 is elevated in bladder tumor tissue and head and neck cancer cell lines (Sturgis et al., 1999; Stronati et al., 2001) . Therefore, the variants of the XRCC7 gene product, if functional, could be expected to have an effect on DSB repair and, thus, on carcinogenesis. Interestingly, we found that the variant genotype GG of XRCC7 Intron 8 had a strong significant association with PCa risk. This is in accordance with a recent study by Gangwar et al. (2009) and Wang et al. (2004) , who also reported significant risk with bladder cancer and glioma, respectively. Conversely, Hirata et al. (2007) did not observe altered risk with PCa. It is well known that frequency of gene polymorphism may vary among ethnic groups. Therefore, the difference in results between these studies may be due to ethnicity differences of the studied populations.
A significant increased risk was observed in G allele carriers with high Gleason grades. To the best of our knowledge, this is the first report demonstrating the risk of the XRCC7 Intron 8 gene polymorphism with PCa. Together, all of these observations suggest that the G allele is a significant risk factor. In support of the functional significance of the XRCC7 Intron 8 polymorphism, XRCC7 is thought to regulate splicing and may cause mRNA instability (Hopfner et al., 2002) . Another possibility is its linkage association with another functional genetic polymorphism. However, these hypotheses are yet to be investigated. Though our study achieved sufficient (>80%) power, as higher sample size might produce different results.
These results suggested that genetic variants involved in DNA repair pathways may also be involved in PCa etiology, particularly when the function of the two genes involved in different DNA repair pathways are both compromised. Additional studies of functional DNA repair gene polymorphisms are required to augment the etiology in the pathogenesis of PCa. 
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